Evidence map›Paper›PMID 42201979›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Long-term antibody dynamics challenge the paradigm of lifelong homotypic immunity to dengue virus.

Jair Andrade, Adrien Mitard de Girardier, Angkana T Huang, Darunee Buddhari, Marco Hamins-Puertolas, Maria-Theresa Alera, Mary Noreen Chua, Taweewun Hunsawong, Derek A T Cummings, Stephen Thomas and 8 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jair Andrade *Department of Genetics, University of Cambridge, Cambridge CB23EH, United Kingdom.ORCID 0000-0002-1412-7868
Adrien Mitard de Girardier *Department of Genetics, University of Cambridge, Cambridge CB23EH, United Kingdom.ORCID 0009-0001-9090-2010
Angkana T Huang *Department of Genetics, University of Cambridge, Cambridge CB23EH, United Kingdom.ORCID 0000-0002-9857-3506
Darunee BuddhariDepartment of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok 10400, Thailand.
Marco Hamins-PuertolasMicrobiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210.ORCID 0000-0002-3631-3637
Maria-Theresa AleraChong Hua Hospital, Cebu City 6000, Philippines.ORCID 0000-0002-6493-190X
Mary Noreen ChuaChong Hua Hospital, Cebu City 6000, Philippines.
Taweewun HunsawongDepartment of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok 10400, Thailand.
Derek A T CummingsDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205.ORCID 0000-0002-9437-1907
Stephen ThomasMicrobiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210.ORCID 0000-0002-8368-7682
Heather FribergViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910.
Jeffrey R CurrierViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910.
Adam WaickmanMicrobiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210.
Aaron FarmerViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910.
In-Kyu YoonInternational Vaccine Institute, Seoul 08826, South Korea.ORCID 0000-0001-5077-6470
Kathryn AndersonMicrobiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210.
Alan L RothmanInstitute for Immunology and Informatics, Department of Cell and Molecular Biology, University of Rhode Island, Providence, RI 02903.ORCID 0000-0002-4064-6848
Henrik SaljeDepartment of Genetics, University of Cambridge, Cambridge CB23EH, United Kingdom.ORCID 0000-0003-3626-4254

Funding

VIRAL DETERMINANTS OF SEVERE DENGUE DISEASEP01AI034533 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ROTHMAN, ALAN L · 1994 to 2022
$42.0M
Identification of serological markers of protection and risk for dengue vaccines and natural infectionR01AI175495 · NIAID · UNIVERSITY OF FLORIDA · PI Derek A Cummings · 2023 to 2026
$2.7M
EC | European Research Council (ERC) 804744Herchel Smith Postdoctoral Fellowship HSPFMilitary Infectious Disease Research Program MIDRPNIAID NIH HHS P01 AI034533NIAID NIH HHS R01 AI175495
6 · The paper itself

Abstract

Immunity following infection with the four dengue virus serotypes (DENV1-4) remains difficult to define. Reports of individuals being reinfected with the same serotype challenge the paradigm that infection induces lifelong homotypic immunity. However, the frequency of these events and their importance for shaping immune profiles remain unknown. Here, we used data from three cohorts (N = 4,268 total participants) in two highly endemic settings (Cebu, Philippines, and Kamphaeng Phet, Thailand), which included long-term follow-up of individuals (mean follow-up of 8.8, 1.9, and 5.0 y). These data allowed us to elucidate age-specific patterns of infection and immunity, and to quantify individual long-term antibody titer dynamics following infection. We formulated mathematical models to explain these patterns, allowing for the possibility of progressive loss of immunity to homotypic reinfection. At the individual level, we found that, in the absence of subsequent infection, antibody titers exhibit a steady long-term decay following incident infections (half-life of 7 to 8 y), with the rate of decay slowing with increasing age. At the population level, incorporating homotypic reinfection was required to explain the age-specific dynamics of infection and immunity observed in our cohorts. We estimated that in highly endemic settings such as the Philippines, 60% of individuals have been homotypically reinfected by the age of 40 y. Our findings highlight homotypic reinfections as a key feature of endemic DENV settings and suggest that vaccines mimicking natural infection might not be expected to provide lifelong protection against infection.

Indexed as

Antibodies, ViralDengueDengue VirusAdolescentAdultChildFemaleHumansMalePhilippinesThailandAntibodies, Viralantibody kineticsdengueepidemiologyforce of infectionimmunity

Identifiers

PMID42201979
PMCPMC13229109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.